Healthy Living: Advanced Melanoma Trial
Patients with metastatic melanoma have faced grim prospects: the American Cancer Society says the five-year survival rate is only 15 percent.
That started changing when the FDA approved Keytruda in 2014. Despite the drug’s success, 60 percent of patients didn’t respond. Researchers at UCLA hope that adding a second drug could cut that number in half.
The combination therapy does have some side effects including flu-like symptoms, injection site irritation, and the possibility of toxic immune responses.
John says most of his side effects went away when he switched to just Keytruda. This trial was small, just 22 participants so far.
For more information you can visit Clinicaltrails.gov